Objective: To investigate the differential effects of acute central administration of distinct fatty acids (FA) on food intake, body weight and energy metabolism. Design: Male Sprague-Dawley rats were treated with bolus intracerebroventricular injections of control hydroxypropylb-cyclodextrin (HPB) or HPB complexed with 30 nmol of saturated palmitic acid (PA), monounsaturated oleic acid (OA) or polyunsaturated o-3 docosahexaenoic acid (DHA). Food intake, body weight, neuropeptide expression and various serum parameters were assessed. Results: When compared with controls, rats injected with either OA or DHA had significantly reduced food intake and body weight for 48 h following injections. No significant changes in food intake or body weight were observed in the PA group. In conjunction with reduced food intake, hypothalamic anorexigenic pro-opiomelanocortin (POMC) gene expression was significantly augmented in the OA and DHA groups, with essentially no changes observed in the PA group. Changes in serum measures of energy metabolism also changed coinciding with the observed differences in food intake. Moreover, central administration of SHU9119, a melanocortin-4-rececptor (MC4R) antagonist, completely abolished the anorexigenic actions of OA, suggesting a role for OA-induced augmentation of hypothalamic POMC expression in mediating its central inhibition of food intake. Conclusions: The hypothalamus differentially senses FA and, specifically, that OA and DHA, but not PA, reduce food intake and body weight, which may be mediated through POMC/MC4R signaling.
Introduction
The hypothalamic melanocortin system has a predominant role in food intake regulation and energy homeostasis. [1] [2] [3] This system consists of heterogeneous sets of neurons, residing primarily in the arcuate nucleus, expressing various orexigenic and anorexigenic neuropeptides. 4 Orexigenic neuropeptides such as neuropeptide Y (NPY) and agouti-related protein, as well as anorexigenic neuropeptides such as those derived from pro-opiomelanocortin (POMC) (for example, a-melanocyte stimulating hormone (a-MSH)), act through multiple mechanisms to control energy homeostasis. [5] [6] [7] Of particular interest are the agonistic effects of POMC-derived a-MSH and the antagonistic effects of agouti-related protein on the melanocortin-3-receptor/melanocortin-4-receptor (MC3R/ MC4R) residing on the paraventricular nucleus through which these neuropeptides exert their effects. 1, 2, 6, 7 Nutrient sensing within the hypothalamus has a critical role in the complex network of signals controlling energy metabolism. [8] [9] [10] In addition to hormonal signals, nutrients crossing the blood-brain barrier, such as glucose and lipids, affect central control of food intake and energy expenditure. 8, 9 Despite a brain preference for glucose as its primary energy source, more recent evidence suggests that hypothalamic lipid metabolism and signaling have significant roles in regulating energy balance, food intake and the etiology of metabolic diseases. 11, 12 For example, much research has focused on the role of hypothalamic de novo lipogenesis and the formation of malonyl-CoA in regulating whole-body energy metabolism. [11] [12] [13] [14] [15] [16] Central administration of FA has also been shown to significantly alter systemic energy metabolism. Intracerebroventricular (i.c.v.) infusion of the monounsaturated FA, oleic acid (OA), acutely reduces food intake and body weight. 17 It appears that i.c.v.-OA increases POMC neuron excitability through direct or indirect actions on potassium channels, 18 but the extent to which neuron excitability contributes to increased POMC expression and action or whether other mechanisms of OA-induced anorexia exist remains indeterminate. In contrast, i.c.v. infusion of the saturated palmitic acid (PA) may have an orexigenic effect and promote weight gain through increased local inflammation with resulting impairment in hypothalamic leptin and insulin signaling. 19, 20 Diets emphasizing different types of fats have been shown to differentially affect neuropeptide expression in the hypothalamus and modulate overall energy expenditure. For example, diets rich in o-6 (n-6) and o-3 (n-3) polyunsaturated FA have been shown to increase POMC expression and decrease NPY expression relative to diets higher in saturated fats. 21, 22 In particular, diets rich in n-3 FA have been shown to promote weight loss with unaltered energy intake. [22] [23] [24] This suggests that n-3 FA promote increased energy expenditure, perhaps in part by increasing FA oxidation pathways and suppressing lipogenic pathways. 25, 26 Diets rich in monounsaturated FA, such as OA, also attenuate weight gain through increased fat oxidation and diet-induced thermogenesis. 27 In contrast, diets high in saturated FA, such as PA, are considered obesogenic and promote systemic resistance to catabolic hormones such as insulin and leptin. 28, 29 It is clear that all fats are not created equal. Different types of fats alter metabolism in various ways via differential signaling pathways. Uncovering the peripheral effects of these different types of fats has been the focus of much research; however, the roles of different FA on central signaling remain largely undiscovered. Based on data concerning the effects of FAs on central neuropeptide expression and food intake regulation, we hypothesize that i.c.v. injections of different FA will result in distinct effects on energy metabolism, with unsaturated FA eliciting a more anorexigenic response compared with the saturated PA.
Materials and methods

Animals
All experiments were carried out in accordance with the University of Minnesota Institutional Animal Care and Use Committee. On arrival, 225-250 g male Sprague-Dawley rats were housed in individual wire-mesh cages and acclimated to a 12-h light-dark cycle, between 0100 (lights on) and 1300 hours (lights off), before surgery. Animals were fed ad libitum Teklad 2018 chow diet and had unlimited access to water. 31 Control animals were injected with 40% HPB. All i.c.v. solutions were dissolved in artificial cerebral spinal fluid (Harvard Apparatus, Holliston, MA, USA) before injections. Injections of 1 ml over the course of 1 min were performed during the 1 h before the dark cycle (1200-1300 hours) following the removal of food at 0900 hours the same morning. Injectors were removed immediately following each injection and were checked to make sure that no bubbles remained on the tips of the injector.
Surgical procedures
Experiment 2: i.c.v. SHU9119 injections The MC4R antagonist SHU9119 (Ac-Nle-cyclo(b-Asp-His-D-2-Nal-Arg-Trp-e-Lys-NH 2 )) (Sigma) was dissolved in and diluted to a concentration of 0.7 nmol ml À1 using artificial cerebral spinal fluid. In place of pure artificial cerebral spinal fluid, the SHU9119/artificial cerebral spinal fluid stock was then used to prepare the final SHU9119 solutions by combining with either 40% HPB or complexed oleate before injection as described for Experiment 1. Each animal in the SHU9119 groups received a 0.5-nmol dose of SHU9119, an amount already shown to significantly reduce food intake up to several days post injection, 32, 33 and each animal given both, SHU9119 and OA, received 30 nmol of OA. OA animals were injected with 30 nmol of OA and control animals with 40% HPB as described in Experiment 1.
The injection procedure and timeline were exactly as described in Experiment 1.
Food intake, body weight and tissue extraction Following injections, animals were given food 15 min before the start of the dark cycle. With the start of the dark cycle as
Effects of central fatty acids DR Schwinkendorf et al t ¼ 0 h, food intake measurements were taken at 4, 24 and 48 h. Food intake was expressed as a percent change from the average intake for the 2 days before injections (that is, basal intake). Body weight measurements were taken daily just before the dark cycle. Animals were killed via anesthetization (60 mg kg À1 nembutal) and decapitation following the 48-h measurements. Blood samples were collected immediately on decapitation and prepared for serum isolation. The hypothalamus was extracted in whole within 2-min of decapitation and put in liquid nitrogen. Both the serum and hypothalamus were stored at À80 1C until further analysis.
RNA isolation and RT-PCR
Total RNA from individual tissues was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) as described by the manufacturer's instructions. Following RNA quantitation, 1 mg of complementary DNA was made using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). RT-PCR was performed on the StepOnePlus RT-PCR System (Applied Biosystems, Foster City, CA, USA) using the iQ SYBR Green Supermix (Bio-Rad). Primers used for RT-PCR analysis are shown in Table 1 .
Serum
Triglycerides (TAG) were assayed using the Triglyceride (Enzymatic) kit (Stanbio Laboratory, Boerne, TX, USA). Free FA (FFA) were assayed using the Free Fatty Acids half-micro test kit (Roche Diagnostics GmbH, Mannheim, Germany). Glucose was assayed using the Autokit Glucose kit (Wako Chemicals, Richmond, VA, USA). b-Hydroxybutyrate was assayed using the b-hydroxybutyrate Liquicolor kit (Stanbio Laboratory). (Figures 1a and b) relative to rats injected with HPB. Similarly, the DHA group experienced a trending reduction in food intake at 24 h (À11.7%; P ¼ 0.06) and this reduction became significant after 48 h (À18%; P ¼ 0.002). Infusion of PA produced no significant differences in food intake when compared with controls at either time point (24 h: þ 4.3%, 48 h: À3%).
Statistical analysis
In conjunction with the food intake data, body weight (expressed as a percent change from the day of injection) was significantly reduced in the OA and DHA groups at both 24 (OA: À1.4%; P ¼ 0.001, DHA: À1.3%; P ¼ 0.02) and 48 h (OA: À1.8%; Po0.001, DHA: À2.2%; Po0.001) (Figures 1c  and d ). In addition, as reflected by the food intake data, the PA group exhibited no significant changes in body weight at either time point when compared with controls (24 h: þ 0.2%, 48 h: þ 0.8%).
POMC expression is increased following i.c.v. injection of OA and DHA To help discover neuronal changes induced by central FA injections that may explain the observed changes in food intake and body weight, we measured hypothalamic neuropeptide expression. Expression of the three neuropeptides, POMC, NPY and agouti-related protein, thought to have key roles in central control of food intake were measured. We also measured expression of UCP2 and CPT1a, genes highly involved in energy and FA metabolism. Expression of POMC, a prominent anorectic neuropeptide, was found to be significantly augmented in the OA (P ¼ 0.03) and DHA (P ¼ 0.01) groups; in contrast, POMC expression remained unaltered in the PA group compared with controls ( Figure 2a) . NPY, a major orexigenic neuropeptide, was found to have significantly augmented the expression in both the DHA (P ¼ 0.02) and PA (P ¼ 0.03) groups when compared Table 1 Primer sequences for qRT-PCR
Gene
Forward primer Reverse primer 
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with controls (Figure 2b ). The OA group exhibited no changes in NPY expression. Expression of another major orexigenic neuropeptide, agouti-related protein, remained relatively stable across all groups, with no significant changes observed (Figure 2c ). Interestingly, expression of UCP2 was significantly higher only in the OA group (P ¼ 0.04), with essentially no changes observed in the DHA or PA groups (Figure 2d) . Finally, as with agouti-related protein, expression of CPT1a was stable across all groups, with no changes observed (Figure 2e ).
Serum analyses following OA, DHA and PA i.c.v. injection Potential peripheral metabolic changes were assessed with measures of serum glucose, TAG, FFA and b-hydroxybutyrate. Despite significant differences in food intake among the different groups, no significant differences in serum glucose or TAG concentrations were observed at 48 h (Figures 3a and b) . Serum FFA concentrations were significantly higher in the OA group (P ¼ 0.03) and were trending up in the DHA group (P ¼ 0.07) (Figure 3c ). No FFA changes were observed in the PA group. Serum b-hydroxybutyrate concentrations were elevated in the OA group (P ¼ 0.01); however, no changes were observed among the other groups when compared with controls ( Figure 3d ).
MC4R inhibition abolishes OA-and DHA-induced anorexia
Mainly in the arcuate nucleus of the hypothalamus, POMC is cleaved to several different proteins, including aMSH, the main anorectic effector of POMC expression. 6 aMSH is then released from POMC-expressing neurons in the arcuate nucleus and binds MC4Rs on neurons residing in the paraventricular nucleus, ultimately activating the downstream anorectic signaling cascades. 6 To determine if increased POMC expression and subsequent a-MSH release was potentially responsible for the observed reductions in food intake and body weight in the OA group, we used the MC4R antagonist, SHU9119, to block downstream POMC effects on food intake. As observed previously, the OA group experienced reductions in both food intake (24 h: P ¼ 0.04, 48 h: P ¼ 0.001) and body weight (24 h: P ¼ 0.001, 48 h: Po0.001); however, these effects were completely abolished by SHU9119 (Figures 4a-d 
Effects of central fatty acids DR Schwinkendorf et al
for augmented POMC expression with subsequent actions in the melanocortin system as an effector of OA-induced anorexia.
Serum analyses following SHU9119 i.c.v. injection Serum analyses were performed following i.c.v. injection of HPB and OA alone or in combination with SHU9119. As observed with serum glucose analyses following injection of the different FA, no significant differences in serum glucose concentrations were observed at 48 h following SHU9119 injections despite changes in food intake and body weight among the groups (Figure 5a ). In contrast, supporting the observed increases in food intake were the significantly elevated serum TAG in both the SHU9119 groups, roughly three times the control concentrations (Figure 5b ) (HPB/SHU9119: Po0.001; OLEATE/SHU9119: P ¼ 0.001). In addition, the OA group had lower concentrations of serum TAG compared with all other groups (versus control: P ¼ 0.03). Differences were also observed in serum FFA concentrations with significantly lower concentrations in both SHU9119 groups (HPB/SHU9119: P ¼ 0.004; OLE-ATE/SHU9119: P ¼ 0.004) and a trending increase in the OA group (P ¼ 0.09) (Figure 5c ). Finally, serum b-hydroxybutyrate concentrations increased in the SHU9119 groups (HPB/SHU9119: P ¼ 0.015; OLEATE/SHU9119: P ¼ 0.004) and decreased in the OA group (P ¼ 0.003) when compared with controls ( Figure 5d ).
Discussion
Central control of food intake is highly involved in energy metabolism and body weight regulation. 4, 8, 10 In addition to isolated central signals, peripheral hormone and nutrient signals also have significant roles in informing the central control centers regarding the metabolic state of peripheral tissues. 4, 8, 10 Although previous research has pointed to the roles of numerous nutrients in controlling hypothalamic signaling, the current studies focused on the documented effects of FA on food intake regulation. 17, 18, 22, 24, 34 Our data support an important role for central FA, specifically in the hypothalamus, in the regulation of food intake and body weight. Following bolus i.c.v. injections, both OA and DHA significantly reduced food intake and body weight over a 48-h period. These effects were not observed with PA, suggesting that mere infusion of FA is not responsible, but rather that distinct signals involving specific FA are most likely involved. The reduction in food intake and body weight following i.c.v.-OA injection has been documented previously, 17 and high central OA concentrations may help explain a portion of the documented attenuation in body weight gain associated with high dietary monounsaturated FA consumption. 27 To our knowledge, no data exist documenting the effects of i.c.v.-DHA injections on food intake or body weight. In this respect, decreased food intake and body weight following i.c.v.-DHA injection are novel findings and potentially provide mechanisms Effects of central fatty acids DR Schwinkendorf et al through which high n-3 polyunsaturated FA consumption leads to body weight stabilization or reduction. [22] [23] [24] In addition, central PA administration did not influence food intake or body weight in this study, but has been shown to promote inflammation along with leptin and insulin resistance in the hypothalamus. 19, 20, 35 Furthermore, diets rich in PA and other saturated fats exert these same malignancies on the peripheral tissues. 28, 29 Our data showed that central OA and DHA, but not PA, augmented hypothalamic POMC expression. Interestingly, orexigenic NPY expression increased in the DHA and PA groups, with no changes observed for the OA group. Expression of the other main orexigenic neuropeptide, agouti-related protein, was similar among all the groups. We believe the elevation in POMC expression was at least partially responsible for the food intake and body weight reductions observed in the OA and DHA groups. The reductions in food intake observed in the DHA group occurred in the presence of both increased anorexigenic POMC and orexigenic NPY expression. This may suggest that other factors, such as time course of POMC and NPY gene expression, POMC and NPY peptide levels and/or receptor levels for POMC-and NPY-related peptides, may also be involved in the changes observed in the DHA group. The PA group exhibited little change in expression of the genes assessed other than a slight increase in NPY expression, which is consistent with the essentially no changes in food intake and body weight observed in this group. Perhaps the increase in NPY expression would lead to increased food intake over longer periods with consistent hypothalamic exposure to high concentrations of PA. Central OA exposure has been shown to increase POMC neuron excitability, 18 and diets rich in monounsaturated FA and polyunsaturated FA (for example, n-3s) have also been shown to increase POMC expression relative to chow or high saturated fat diets. 21, 24 Interestingly, diets rich in saturated fats have been shown to decrease orexigenic neuropeptide expression. 21, 24 Despite documented attenuation of orexigenic neuropeptide expression, an obesogenic drive is still induced by diets rich in saturated FA such as PA. 24 More research is needed to better define the various FA-induced changes in neuropeptide expression affecting food intake as discrepancies still exist in the literature; however, based on our observations, it appears that OA-and DHA-induced increases in POMC expression lead to decreased food intake and body weight in the short term.
To help support the hypothesis of increased POMC expression leading to the observed reductions in food intake and body weight in the OA group, we co-injected the MC4R inhibitor SHU9119 with OA. Our observations support a strong orexigenic effect of i.c.v.-SHU9119. SHU9119 injection completely removed any signs of OA-induced anorexia. Furthermore, both the HPB/SHU9119 and OA/SHU9119 groups experienced significant increases in both food intake 
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DR Schwinkendorf et al and body weight over 24 and 48 h. The fact that SHU9119 removed OA-induced anorexia does not by itself prove that augmentation of POMC expression and MCR signaling is responsible for the reductions in food intake and body weight following i.c.v.-OA, but it does provide strong support for this hypothesis. Taken together, these data support an important role for POMC expression and subsequent melanocortin system signaling in OA-induced anorexia. Central nervous system fuel sensing, especially in the hypothalamus, is thought to be significantly involved in energy homeostasis both centrally and peripherally. 8, 10 Both central administration of OA 17 and systemic OA-based lipid infusions 36 have been shown to inhibit hepatic glucose production and support glucose homeostasis through hypothalamic lipid sensing. We measured serum glucose, TAGs, FFA and b-hydroxybutyrate concentrations to gain insight into the effects of central FA administration along with induced changes in food intake and body weight on peripheral metabolism. With the significant differences in food intake among all the treatment groups in both experiments, one may suspect differences in serum glucose concentrations; however, we observed no significant changes in serum glucose concentrations among any of the groups, even in the SHU9119 groups where food intakes were increased roughly by 50%. Thus, it is likely that there were differences in peripheral glucose metabolism between treatments, although the exact mechanism explaining these findings remains unknown. In contrast to serum glucose, other serum parameters measured changed, as would be expected based on changes in food intake. Overall, our data support a role for FA-induced changes in neuropeptide expression in mediating the central regulation of food intake and body weight. Specifically, central administration of OA or DHA increased POMC expression and led to significant reductions in both food intake and body weight when compared with controls and animals receiving PA injections. In addition, signaling through the melanocortin system appears to mediate the effects of these unsaturated FA on food intake and body weight. Moreover, given the general lack of knowledge on the transport, metabolism and signaling of FA or downstream metabolites in the brain, these studies point toward a need for future research that attempts to characterize central FA metabolism and identifies how diets differing in FA composition elicit differential effects on central signaling and whole body energy metabolism.
